Abbott (ABT) Tops Q1 EPS by 5c, FY Guidance Unchanged

Abbott (NYSE: ABT) reported Q1 EPS of $0.48, $0.05 better than the analyst estimate of $0.43. Revenue for the quarter came in at $6.34 billion versus the consensus estimate of $6.16 billion.

ABBOTT'S FULL-YEAR EARNINGS-PER-SHARE GUIDANCE REMAINS UNCHANGED

Abbott continues to project earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $0.92 to $1.02, including amortization and integration expenses related to the acquisition of St. Jude Medical. Projected adjusted diluted earnings per share from continuing operations remains unchanged at $2.40 to $2.50 for the full year 2017.

Abbott forecasts net specified items for the full year 2017 of approximately $1.48 per share. Specified items include acquisition-related expenses, intangible amortization expense, charges associated with cost reduction initiatives and other expenses, partially offset by a gain on the sale of the AMO business.

For earnings history and earnings-related data on Abbott (ABT) click here.

You May Also Be Interested In

• Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Reading (RDI) Tops Q2 EPS by 4c